Canifug Cremolum, containing Clotrimazole, is used in situations involving certain distressing symptoms within the gynecological domain. This product is commonly used to manage acute episodes of fungal overgrowth.

This medication is specifically used for managing conditions characterized by periods of heightened symptoms, such as vulvovaginal candidiasis (vaginal yeast infection) or thrush. It is relevant in situations involving an infectious overgrowth by Candida species, and may be part of symptomatic management across this therapeutic domain.

Alleviation of Localized Distress Symptoms

The treatment is relevant for managing symptoms related to inflammatory or irritative states, including intense itching (pruritus), a burning sensation, and soreness in the vulvovaginal area. It also helps address the abnormal discharge that often characterizes the infection.

The product is applied in addressing symptom clusters that may become intense or disruptive, assisting with maintaining functional stability during these episodes. This symptomatic management supports day-to-day comfort during periods of heightened physical discomfort.

Summary of Therapeutic Focus
Main Condition: Vulvovaginal candidiasis
Key Symptoms Addressed: Itching, burning, soreness, and discharge
Primary Benefit: Contributes to improved comfort during periods of heightened symptoms

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Map: Who can and cannot use Canifug Cremolum

Official regulatory documents define the eligible population for Canifug Cremolum (Clotrimazole vaginal ovule) based on contraindications, age restrictions, and specific clinical conditions.

Eligibility Scope

Classification	Population Rule	Status Defined by Regulators
Contraindicated	Patients with known hypersensitivity to the active substance Clotrimazole or any product excipients.	Must not use
Age Restriction	Females under 16 years of age.	Not recommended; requires medical consultation
	Older adults (aged 60 and over).	Conditional use; requires medical consultation
Pregnancy/Lactation	First Trimester of Pregnancy.	Preferably avoided
	Second/Third Trimester of Pregnancy.	Conditional use; permitted under medical supervision only
	Lactation/Breastfeeding.	Generally permitted (minimal systemic absorption)
Conditional Use	Patients with atypical symptoms (e.g., fever, ulcers, abdominal pain, irregular bleeding).	Self-treatment restricted; requires medical advice
	Patients with recurrent infections (more than two in six months).	Self-treatment restricted; requires medical advice
Operational Limit	Use during the menstrual period.	Not recommended; may impair efficacy

Resulting Eligibility Structure

Regulatory documents establish absolute contraindication based on ingredient sensitivity. Eligibility is restricted by age, as the medicine is generally not recommended for individuals under 16 or for older adults (60+) without prior medical consultation. Use during pregnancy is conditional upon medical supervision and is limited by trimester. The label also restricts self-treatment eligibility based on the nature and history of symptoms, requiring medical consultation for atypical presentation or frequent recurrence.

Interactions with other medicines and products

This section describes the officially documented patterns of interaction for the active ingredient Clotrimazole as published in government regulatory sources.

Drug-Drug Interactions The co-administration of this product with certain oral medicinal products is formally documented due to effects on systemic exposure. Specifically, concurrent use with the immunosuppressant medicines Tacrolimus or Sirolimus may result in an increase in the plasma levels of these agents. This pharmacokinetic outcome is linked to potential inhibition of specific metabolic pathways. Separately, a pharmacodynamic interaction is noted with other antifungal medicines: the use of Clotrimazole can reduce the efficacy of polyene antifungal antibiotics, such as Amphotericin B and Nystatin.

Product and Administration Restrictions Strict restrictions are placed on co-administered vaginal items and barrier contraceptives. Tampons, intravaginal douches, spermicides, or other vaginal products are prohibited from use concurrently during the treatment period. A significant interaction is documented with latex or rubber barrier contraceptives, including condoms and diaphragms. The product is known to cause physical damage to the material of these devices, which can severely reduce their protective effectiveness and safety. Users are required to employ alternative, non-latex forms of contraception throughout the treatment and for a mandatory period of at least five days after treatment completion. No interactions with food, alcohol, or common herbal products are formally documented for this specific localized formulation.

Targeted Blockade of Fungal Ergosterol Synthesis

The core action of Clotrimazole is the inhibition of lanosterol 14-alpha-demethylase (CYP51), a key enzyme in the fungal cell's metabolic machinery. Clotrimazole acts as a non-competitive inhibitor, binding to the heme group of the enzyme. By blocking this enzyme, the drug prevents the conversion of lanosterol into ergosterol, the fundamental sterol required for fungal membrane integrity.

---

Disruption of Fungal Cell Membrane Integrity

The resulting lack of structural ergosterol and the build-up of toxic 14-alpha-methylated sterol intermediates critically compromise the permeability and fluidity of the fungal cell membrane. This damage leads to the uncontrolled leakage of essential intracellular contents and disruption of membrane-bound enzyme systems. This cellular dysfunction leads to the cessation of the pathogen's reproductive capacity and results in fungicidal (cell-killing) or fungistatic (growth-arresting) physiological effects.

---

Mechanism Limitations: Resistance and Efflux

The functional capacity of the mechanism can be constrained by the fungal pathogen itself through the development of acquired resistance. This typically involves genetic mutations in the CYP51 enzyme that alter its structure, preventing Clotrimazole from achieving the necessary binding affinity, or the activation of efflux pumps that actively expel the drug from the cell.

Canifug Cremolum is a specific Clotrimazole formulation intended exclusively for intravaginal administration. The established usage protocol involves a short-term, fixed-duration course designed to deliver the active substance locally.

Usage patterns for adults typically utilize three core regimens, determined by the unit strength. This includes a single-dose regimen using one 500 mg vaginal unit, a short course using one 200 mg unit once daily for three days, or an extended course requiring one 100 mg unit administered once daily for six or seven consecutive days. A second course of treatment is recognized if symptoms persist or reoccur following the initial regimen.

Administration Timing and Procedural Restrictions

To ensure optimal dissolution and retention, the administration must occur once daily, preferably at night (bedtime), while the user is lying on their back. Certain use-context constraints apply to the application. Treatment must not be undertaken during menstruation and should be completed beforehand.

Furthermore, simultaneous use of other vaginal products, such as tampons, douches, or spermicides, is restricted. A critical administration constraint is the product’s potential to reduce the effectiveness of rubber contraceptives, requiring users to employ alternative precautions for at least five days following use. In the pediatric population, usage is generally restricted to individuals 16 years of age and older.

Canifug Cremolum: Recent Clinical Evidence

Canifug Cremolum contains clotrimazole, an established antifungal agent used for treating vulvovaginal candidosis (vaginal yeast infection). The formulation is a vaginal suppository designed for local treatment. Clinical studies and extensive therapeutic use over decades have confirmed the role of clotrimazole in managing this condition.

---

Efficacy and Treatment Outcomes

Clinical data, including multiple randomized controlled studies, have explored the efficacy of intravaginal clotrimazole for uncomplicated vulvovaginal candidosis. These studies indicate that single, high-dose applications of the compound are associated with high mycological cure rates and are comparable to multi-day, lower-dose regimens. Single-dose treatments of 500 mg have been observed to achieve outcomes similar to those from multiple lower doses.

Research has also investigated the compound's use in complicated cases, such as recurrent infections. In these instances, induction treatment for one to two weeks, followed by intermittent topical application, has been explored to maintain remission. Studies suggest high short-term mycological cure rates following the induction phase.

---

Safety and Tolerability Profile

The safety profile of intravaginal clotrimazole has been extensively studied. Due to its poor oral bioavailability, only a small percentage of the dose is typically absorbed into the systemic circulation, which contributes to a favorable systemic tolerability profile.

• Adverse Events: Local adverse events, such as mild irritation or burning at the site of application, are reported at low rates. These events are generally non-serious and do not commonly lead to the discontinuation of treatment.
• Use in Pregnancy: Studies involving symptomatic pregnant women found that one-week treatments with topical clotrimazole were associated with high mycological cure rates. Furthermore, research has explored whether the use of the compound during pregnancy may be associated with a reduced risk of Candida infection in newborns.

Overall, evidence from clinical trials and long-term surveillance indicates that topical clotrimazole formulations are generally well-tolerated in the management of vulvovaginal candidosis.

Common questions about Canifug Cremolum (FAQ)

Q: What is Canifug Cremolum and what is it used for?

A: Canifug Cremolum is a vaginal suppository containing the active ingredient clotrimazole, an antifungal medication. It's used to treat vaginal candidiasis (also known as a yeast infection or thrush) which is caused by fungi, primarily Candida species.

---

Q: How should I use Canifug Cremolum?

A: Canifug Cremolum is intended for vaginal use only. The standard recommended treatment involves inserting one Cremolum suppository as deep as possible into the vagina, preferably in the evening before going to bed. This is typically a three-day course of treatment. It is important to continue the treatment for the full three days, even if symptoms improve quickly, to ensure the infection is fully cleared.

---

Q: When is the best time to use the Cremolum?

A: It is generally recommended to insert the Cremolum in the evening before bedtime. This allows the medication to dissolve and work overnight while you are lying down, which can help prevent the product from leaking out immediately.

---

Q: Can I use Canifug Cremolum during my menstrual period?

A: While the active ingredient, clotrimazole, remains effective during menstruation, it is generally recommended to avoid starting treatment with vaginal suppositories like Canifug Cremolum during the period. The flow of blood may reduce the effectiveness by washing some of the medication out. If the period begins during the treatment course, it is best to consult a healthcare provider for advice on whether to pause or continue the treatment.

---

Q: What should I do if I forget to use a dose?

A: If you forget to use a Cremolum, insert it as soon as you remember. However, if it is almost time for your next dose (e.g., the following evening), skip the missed dose and continue with your regular schedule. Do not use two Cremolum suppositories at the same time to make up for a missed dose.

---

Q: What are the common side effects of Canifug Cremolum?

A: Common side effects are usually local and mild. They may include:

• Burning or irritation in the vaginal area.
• Itching (pruritus).
• Redness or swelling.

These effects are often temporary and can sometimes be a reaction to the infection itself. If these symptoms are severe or persist, you should stop the treatment and consult a healthcare provider.

---

Q: Can Canifug Cremolum be used during pregnancy or breastfeeding?

A: If you are pregnant or breastfeeding, you must consult your doctor or pharmacist before using Canifug Cremolum. In pregnant women, the use of vaginal products containing clotrimazole is often recommended, but it should be done under medical supervision and only if clearly necessary, especially during the first trimester. Your doctor will weigh the benefits against the risks.

---

Q: Does Canifug Cremolum affect other medications, or is it affected by them?

A: Clotrimazole from vaginal suppositories is generally poorly absorbed into the bloodstream, meaning the risk of systemic drug interactions is low. However, it is important to inform your doctor or pharmacist about all other medicines you are currently taking, including those obtained without a prescription. Clotrimazole may interact with certain drugs metabolized by the liver, but this is less common with topical preparations. There is a potential for clotrimazole products to reduce the effectiveness of latex contraceptives like condoms or diaphragms, so alternative contraception should be used during treatment and for five days afterward.

---

Q: How will I know if the infection is cured?

A: You should notice a reduction in symptoms such as itching, discharge, and burning usually within a few days of starting treatment. For the best chance of a full cure, it is essential to complete the full three-day course of Canifug Cremolum, even if your symptoms have completely disappeared earlier. If your symptoms have not improved after the three-day course, or if they worsen, you must consult your healthcare provider.

---

Q: Does Canifug Cremolum contain ingredients that can stain clothing?

A: The Cremolum suppository contains base ingredients that may soften or dissolve. It is common for some of the product to leak out of the vagina after insertion. It is recommended to wear a panty liner to protect clothing, as some leakage may cause faint staining.

How to Store and Dispose of Canifug Cremolum?

The storage and disposal of Canifug Cremolum must strictly adhere to the conditions mandated by official regulatory labeling to ensure product stability and safety.

Storage Requirements

Condition	Requirement
Temperature	Store below 25 C (77 F).
Prohibition	Do not freeze the product.
Container	Keep in the original container/blister pack.
Shelf-Life	Do not use after the expiry date (EXP) on the packaging.
Child Safety	Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Canifug Cremolum must not be disposed of via wastewater or household waste, as mandated for pharmaceutical waste. Patients must consult a pharmacist for the proper procedure on how to return or dispose of the medication.